Lilly to Present Obesity Drug Data at ObesityWeek 2026
Lilly says it will present data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026. The body begins to reference Phase 2 results for EloraTZP but is truncated.
Lilly says it will present data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026. The body begins to reference Phase 2 results for EloraTZP but is truncated.